SABR for Renal Tumors

University Health Network, Toronto

Status

Enrolling

Conditions

Renal Tumor

Treatments

Radiation: Stereotactic Ablative Radiotherapy

Study type

Interventional

Funder types

Other

Identifiers

NCT03747133

18-5481

Details and patient eligibility

About

Renal Cell Carcinoma (RCC) is the most common type of kidney cancer. The usual treatment for this type of cancer is surgery. Considering the most common patients are an average age of 65 and some are not suitable candiates for surgery, there is great interest in non-surgical alternatives for kidney cancer treatments. This study will investigate the use of Stereotactic Ablative Radiosurgery (SABR) for renal tumors. SABR is a non-invasive alternative, which involves delivery of high doses of radiation to the target, while minimizing the risk of injury to the surrounding organs. Patients will be seen before and end of treatmetn and will be followed at 4 month intervals for up to 2 years. During the follow ups, patients will be asked to complete a quality of life questionnaire and will have standard of care imaging.

Enrollment

45 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Solid Kidney Mass (primary RCC or metastasis) amenable to SABR ≤6cm
Histological or radiological diagnosis of renal tumor
Inoperable: High risk for surgery or declined surgery
ECOG performance status of 0-3

Exclusion criteria

≥5 active metastases
Sysstemic therapy (except endocrine therapy) wthin 6 days prior to SABR
Prior abdominal radiotherapy with fields overlap resulting in excessive doses to the involved kidney
Patients with end stage renal failure > 4(KDOQI guidelines)
Familial Syndrome: Von Hippel-Lindau disease, Polycystic Kidney Disease, Hereditary Papillary RCC or Tuber Sclerosis